Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  15.00 4.45% 352.00 173,074 16:35:20
Bid Price Offer Price High Price Low Price Open Price
342.00 348.00 351.00 328.00 347.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 154.49 -106.40 -12.06 2,431
Last Trade Time Trade Type Trade Size Trade Price Currency
17:04:14 O 231 339.944 GBX

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
28/5/202009:48(Chi-Med)Hutchinson China Meditech Limited2,630
31/7/201807:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201810:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-05-28 16:04:21339.94231785.27O
2020-05-28 15:35:20352.003511,235.52UT
2020-05-28 15:29:53348.001034.80AT
2020-05-28 15:28:35347.004001,388.00AT
2020-05-28 15:28:35347.00100347.00AT
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 337p.
Hutchison China Meditech Limited has a 4 week average price of 314p and a 12 week average price of 250p.
The 1 year high share price is 478p while the 1 year low share price is currently 250p.
There are currently 690,574,765 shares in issue and the average daily traded volume is 109,117 shares. The market capitalisation of Hutchison China Meditech Limited is £2,430,823,172.80.
lauders: I'm not selling for another 9 years but I hope they do not keep doing this, as it just keeps destroying any value they create. Employees and Management with stock options must be reeling. I feel for the employees but since the management, some of them anyway, took the decision to proceed with the placing my feelings for them are somehow not so pleasant. Perhaps the BOD will show us how much of an over-reaction this is by buying more shares in the market? That would at least help in some way and no doubt help them a lot more in years to come when they make the profit on the buys that we all hope will follow with a much higher share price. If the share price can stay around these levels until mid-week next week even I will probably top-up!
its the oxman: Always frustrating when share price falls but we need to keep in mind it is often what institutions demand and HCMs prospects will be stronger if it stays well financed. It was also done from a reasonable position of share price strength. For me as long as co keeps delivering and drug progress continues , value will keep building so all is good and this will be a small blip.
steeplejack: Perhaps.I hoped that this placing was driven by an institutional request for stock but the price isn’t suggesting that.Book builds are transparent and the share price is suggesting a placing ar $27 or 410p equivalent.Given the shares were a good 10% higher a couple of days ago,not overly pleasing.
hamsterdam: If HCM announce they are delisting from AIM is it likely to have a major negative impact on the share price?
lauders: HCM gets a mention in this review of 2019 and look ahead at 2020: Https:// On a more hopeful note, China's active domestic life sciences sector is rising to meet the country's demands for homegrown innovative medicines, as exemplified by Innovent Biologics Inc.'s Tyvyt (sintilimab) and Hutchison China Meditech Ltd.'s Elunate (fruquintinib). Encouragingly for cross-border ties, some of the most innovative projects are being built on cross-border partnerships with U.S.-based companies, such as those between Nanjing Legend Biotech Co. Ltd. and Janssen Biotech Inc. and CASI Pharmaceuticals Inc., of Rockville, Md., and its Chinese partner, Juventas Cell Therapy Ltd., of Beijing. The pairs, co-developers of two investigational CAR T therapies that entered the clinic in December, seem to suggest that despite trade turbulence, the collaborative spirit at the core of global biopharma innovation remains strong. With luck 2020 will be a much better year for HCM as far as the share price goes. The company will no doubt continue on its path no matter what happens.
nerdofsteel: Great update session by our CEO today at the short DB Investor event, I particularly picked up on these aspects in response to some questions submitted via the DB portal 1. There is still an appetite and the Company does see value in a HK listing, once the share price recovers after the CKHH deconsolidation 2. NRDL Elunate update could come very shortly (within the next couple of weeks) 3. The Company is confident that the excellent and material pipeline progression should see the share price recover back to previous levels 4. Savo is well on track for NDA submission in around March 2020 in China for Exon 14 del
nerdofsteel: Now CKHH have reduce their holding below 50% let's hope we can get back to a proper valuation. Edison value the shares at £6.99 per share based on a DCF model, cash and IP. HCM’s recent share price underperformance provides an opportunity to revisit the investment case. We believe the long-term investment case is solid, with multiple near-term catalysts (regulatory filing and potential approval for surufatinib and savolitinib) as HCM successfully launches numerous assets to market (~2020/21 and beyond) in China and internationally. Its broad mid- to late-stage innovation platform (IP) will translate into diverse global revenue streams with a multitude of other compounds coming to the fore from HCM’s established and proven innovative R&D platform. Existing partnering deals for savolitinib and fruquintinib support the investment case as milestones and royalties on sales continue to bolster the P&L. HCM has global strategic aspirations, and it is only a matter of when rather than if its aspirations are met, in our view. HCM continues to invest in expanding its global innovation organisation; it now has >440 scientific personnel based in China and the US (Shanghai, Suzhou and New Jersey).
steeplejack: Indeed,an exciting test result would of course reverse the slide in the share price but I question whether the fall in the shares has been in anyway predictable.The erratic behaviour of the parent company is largely responsible for HCMs fall from grace.The decision to deconsolidate the subsidiary involved a pulled placing in Hong Kong.Without warning,the placing was hastily relocated to the Nasdaq to be executed by only one broker,Morgan Stanley,rather than the coterie of brokers (including Goldmans)originally planned to do the Hong Kong placing.The 24 dollar placing was badly handled and is primarily responsible for the price decline pre and post the issue.This is even more apparent in view of the recent successful placing professionally executed at $17.65.Benefit of hindsight is a erroneous commodity.If the fall in the share price was so very predictable,I feel sure that we would have seen a lot of shorting by those canny hedge funds.
thornyone: The HCM share price has been behaving predictably. From January 2018 the news has been solidly negative and this is reflected in the price dropping from $40 to $17 in waves. However, more than a reversal of these numbers is possible as soon as a globally exciting test result is received. Everything else, such as publicity about pipelines and listings is just a distracting sideshow.
waldron: 30/09/2019 3:08pm Dow Jones News Hutchison China Meditech (LSE:HCM) Intraday Stock Chart Today : Monday 30 September 2019 Click Here for more Hutchison China Meditech Charts. (Adds pricing of the offer, updates share price) By Adria Calatayud London-listed shares in Hutchison China MediTech Ltd. (HCM.LN) fell Monday after the company said shareholder CK Hutchison Holdings Ltd. (0001.HK) plans to sell a 1.3% stake. This would reduce CK Hutchison's stake in the company to 49.9% from 51.1%, allowing it to deconsolidate the investment from its financial statements, Hutchison China MediTech said. The offering price was set at $17.65 for each American depositary share, Hutchison China MediTech said. Each ADS represents five ordinary shares, the company said. The China-focused pharmaceutical company, which is listed in the U.K. and the U.S., said the Hong Kong-based conglomerate has no intention of selling additional shares in Hutchison China MediTech for the foreseeable future upon completion of the current offering. Hutchison China MediTech's London-listed shares at 1320 GMT were down 5% at 285 pence. Write to Adria Calatayud at (END) Dow Jones Newswires September 30, 2019 09:53 ET (13:53 GMT)
Hutchison China Meditech share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200529 04:15:53